کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3253838 | 1207163 | 2011 | 8 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Peregrinaje de un antidiabético hasta su aprobación por las agencias internacionales del medicamento. Situación actual
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
غدد درون ریز، دیابت و متابولیسم
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Peregrinaje de un antidiabético hasta su aprobación por las agencias internacionales del medicamento. Situación actual Peregrinaje de un antidiabético hasta su aprobación por las agencias internacionales del medicamento. Situación actual](/preview/png/3253838.png)
چکیده انگلیسی
The approval process for new antidiabetic drugs has been radically transformed, involving the scope, extension and objectives of their clinical development. The endpoints, type and duration of the clinical trials, and which ones need to be completed before and after the marketing authorization, have been debated. The US and European Regulatory Agencies have established new requirements for the clinical development of antidiabetic drugs, with special emphasis on cardiovascular safety. New antidiabetic drugs will need proof of efficacy in terms of glycemic control, in monotherapy and/or in combination therapy, as well as sufficient cardiovascular safety, assessed by an integrated analysis of cardiovascular events performed by an independent Event Adjudication Committee. In some cases, specific safety studies with cardiovascular events as primary endpoints may be necessary. The time needed to complete the clinical development of new antidiabetic drugs may be extended by 2-3 years.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Avances en DiabetologÃa - Volume 27, Issue 4, JulyâAugust 2011, Pages 107-114
Journal: Avances en DiabetologÃa - Volume 27, Issue 4, JulyâAugust 2011, Pages 107-114
نویسندگان
Rafael Ortega Basagoiti,